| 2025-02-14 | +0.66 % |
|
| 2025-02-11 | +0.4 % |
|
| 2025-02-05 | +0.79 % |
|
| 2025-02-04 | +0.49 % |
|
| 2025-01-31 | -1.27 % |
|
| 2025-01-28 | -0.52 % |
|
| 2025-01-24 | +1.05 % |
|
| 2025-01-17 | +1.06 % |
|
| 2025-01-16 | +2.06 % |
|
| 2025-01-15 | +0.18 % |
|
| 2025-01-13 | +1.4 % |
|
| 2025-01-10 | -2.44 % |
|
| 2025-01-07 | +0.04 % |
|
| 2025-01-06 | -1.37 % |
|
| 2025-01-03 | +0.91 % |
|
| 2025-01-02 | +0.43 % |
|
| 2024-12-27 | -1.05 % |
|
| 2024-12-19 | -0.05 % |
|
| 2024-12-17 | +0.02 % |
|
| 2024-12-16 | -1.37 % |
|
| 2024-12-09 | -0.06 % |
|
| 2024-12-06 | -0.15 % |
|
| 2024-12-04 | -0.46 % |
|
| 2024-12-02 | |
|
| 2024-11-27 | +0.69 % |
|
| 2024-11-26 | -0.08 % |
|
| 2024-11-25 | -0.53 % |
|
| 2024-11-22 | +1.73 % |
|
| 2024-11-21 | +0.75 % |
|
| 2024-11-20 | -1.05 % |
|
| 2024-11-19 | -2.96 % |
|
| 2024-11-18 | +0.07 % |
|
| 2024-10-31 | -1.38 % |
|
| 2024-10-30 | +0.2 % |
|
| 2024-10-29 | -0.31 % |
|
| 2024-10-28 | +0.01 % |
|
| 2024-10-25 | -0.44 % |
|
| 2024-10-23 | +1.26 % |
|
| 2024-10-22 | +0.1 % |
|
| 2024-10-21 | -1.31 % |
|
| 2024-10-18 | +2.73 % |
|
| 2024-10-17 | -0.22 % |
|
| 2024-10-16 | +0.17 % |
|
| 2024-10-15 | -0.19 % |
|
| 2024-10-14 | +0.73 % |
|
| 2024-10-11 | +0.57 % |
|
| 2024-10-10 | +0.57 % |
|
| 2024-10-09 | +0.24 % |
- The article discusses recent institutional investment activities in McDonald's Co. (NYSE:MCD) stock, which saw a slight increase of 0.24%, highlighting various changes in holdings by investors and analysts' price targets.
The increase in Medtronic (MDT) stock is not directly addressed in the article; however, general market trends, positive earnings outlooks, or strategic moves by the company could be influencing factors behind stock price rises.
- Medtronic (MDT) stock rose by 0.24% recently, likely due to strong quarterly earnings that exceeded analyst expectations, as well as increased price targets and favorable ratings from multiple research firms.
- Medtronic (MDT) stock rose 0.24% following significant increases in institutional investments, positive analyst ratings updates, and successful earnings reports that exceeded expectations.
The stock's rise can be attributed to substantial buying activity from institutional investors, positive revisions from analysts regarding price targets, and continued revenue and earnings growth as reported in their quarterly earnings.
- Medtronic (MDT) stock saw a slight increase of 0.24% following a reported reduction in holdings by Partnership Wealth Management LLC, which may indicate market adjustments and investor sentiments amidst ongoing changes in institutional investments.
- Medtronic (MDT) stock increased by 0.24% due to a combination of positive analyst reports raising price targets and the company's strong earnings performance that exceeded expectations during the last quarter.
|
| 2024-10-08 | +1.26 % |
|
| 2024-10-04 | +0.56 % |
|
| 2024-10-03 | -1.51 % |
|
| 2024-10-02 | -0.98 % |
|
| 2024-10-01 | -0.03 % |
|
| 2024-09-26 | +0.07 % |
|
| 2024-09-25 | -0.41 % |
|
| 2024-09-24 | -0.11 % |
|
| 2024-09-20 | -0.15 % |
|
| 2024-09-17 | -1.64 % |
|
| 2024-09-13 | |
|
| 2024-09-10 | +0.41 % |
|
| 2024-09-06 | +0.56 % |
- Medtronic (MDT) stock rose 0.56% due to increased options trading, positive quarterly earnings results that exceeded analyst expectations, and favorable upgrades in price targets from multiple equity research analysts.
- The Medtronic (MDT) stock increased by 0.56% following positive market sentiment driven by its collaboration with Orchestra BioMed, which has received a Buy rating and a favorable price target from analysts, indicating confidence in the company's innovative approaches and potential for success in product development.
- The article discusses the increasing global burden of gastrointestinal cancers, noting a rise in incidence and death rates, particularly for colorectal, pancreatic, and liver cancers from metabolic dysfunction.
Medtronic (MDT) stock likely rose by 0.56% due to positive market sentiment or investor confidence influenced by its involvement in medical technologies related to cancer treatment and management, as suggested by the mention of the company's research grants in the context of gastrointestinal cancer.
- Medtronic (MDT) stock rose by 0.56% likely due to increased investing activity from institutional investors, positive analyst upgrades on target prices, and a recent earnings report that exceeded expectations, indicating financial stability and growth potential.
|
| 2024-09-03 | +0.43 % |
|